Luteinizing hormone is independently associated with high‐sensitive cardiac troponin T elevation in postmenopausal T2DM patients: A cross‐sectional study
Open Access
- 22 October 2024
- journal article
- research article
- Published by Wiley in Journal of Diabetes
- Vol. 16 (10) , e70005
Abstract
Background: It is known that the risk of ischemic heart disease increases in patients with type 2 diabetes mellitus (T2DM). For female patients, the incidence of heart disease can be even greater after menopause, accompanied by dramatic changes in sex hormones. We investigated the correlations between sex hormones and markers of ischemic heart diseases in postmenopausal females with T2DM patients.Methods: This cross‐sectional study collected data from 324 hospitalized postmenopausal females with T2DM. Multiple linear regression analyses were conducted to determine the correlations between sex hormones and cardiac markers including high‐sensitive cardiac troponin T (hs‐cTnT) and N‐terminal prohormone of brain natriuretic peptide (NT‐proBNP) levels.Results: Multiple linear regression analyses revealed that luteinizing hormone (LH) was positively and independently associated with hs‐cTnT concentrations in postmenopausal females with T2DM (β = 0.189, p = 0.002). Postmenopausal females with T2DM and subclinical myocardial injury had higher LH levels than those without subclinical myocardial injury (29.67 vs. 25.08 mIU/mL, p < 0.001). A multivariate logistic regression analysis confirmed an independent and significant association between elevated LH and subclinical myocardial injury in postmenopausal females with T2DM (adjusted odds ratio [OR] = 1.077, 95% confidence interval [CI], 1.033–1.124; p < 0.001). As another gonadotropin, the follicle‐stimulating hormone did not show independent correlations with hs‐cTnT or NT‐proBNP (p > 0.05). Neither estrogen nor testosterone was correlated with cardiac markers.Conclusions: Elevated LH levels were positively and independently associated with increased hs‐cTnT levels in postmenopausal women with T2DM. Our findings suggest that LH could serve as a potential marker for assessing the risk of subclinical myocardial injury in postmenopausal females with T2DM. imageKeywords
This publication has 53 references indexed in Scilit:
- Detectable Subclinical Myocardial Necrosis Is Associated With Cardiovascular Risk in Stable Patients With DiabetesDiabetes Care, 2013
- Cardiac Troponin T Measured by a Highly Sensitive Assay Predicts Coronary Heart Disease, Heart Failure, and Mortality in the Atherosclerosis Risk in Communities StudyCirculation, 2011
- Endogenous hormones and coronary heart disease in postmenopausal womenAtherosclerosis, 2011
- The association of luteinizing hormone and follicle-stimulating hormone with cytokines and markers of disease activity in rheumatoid arthritis: a case–control studyScandinavian Journal of Rheumatology, 2010
- Subclinical Myocardial Necrosis and Cardiovascular Risk in Stable Patients Undergoing Elective Cardiac EvaluationArteriosclerosis, Thrombosis, and Vascular Biology, 2010
- A Sensitive Cardiac Troponin T Assay in Stable Coronary Artery DiseaseNew England Journal of Medicine, 2009
- LH/HCG stimulation of VEGF and adrenomedullin production by follicular fluid macrophages and luteinized granulosa cellsReproductive BioMedicine Online, 2009
- The Contribution of Luteinizing Hormone to Alzheimer Disease PathogenesisClinical Medicine & Research, 2007
- Is Diabetic Retinopathy an Independent Risk Factor For Ischemic Stroke?Stroke, 2007
- Retinopathy as a Risk Factor for Nonembolic Stroke in Diabetic SubjectsStroke, 1995